Price T Rowe Associates Inc Centessa Pharmaceuticals PLC Call Options Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CNTA
# of Institutions
107Shares Held
118MCall Options Held
5.9KPut Options Held
53K-
Medicxi Ventures Management (Jersey) LTD20MShares$349 Million66.33% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$174 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$169 Million4.42% of portfolio
-
Perceptive Advisors LLC New York, NY6.28MShares$110 Million2.62% of portfolio
-
First Light Asset Management, LLC Edina, MN5.94MShares$104 Million8.27% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.65B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...